I wouldn't say they are "a" weakness.
They're certainly competent but seem to lack the commercial cunning you might expect from a junior.
Cottee has it in spades.
These guys are far too earnest.
The critical dependency for NWE is cash.
Can they get the SP high enough before they run out of their 4m or so?
Instead on the journey they discover something new and they go "oh! what's this? Let's have a dabble shall we?" when they really should have focused on getting to the the Carynginia ASAP, get the SP up and then raise enough capital to secure the company's future prospects.
They haven't done that so now they better be sure they can get the results in time to raise more capital.
- Forums
- ASX - By Stock
- NWE
- moving buy/sell
moving buy/sell, page-34
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NWE (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online